About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

11/03/2026  |  Bree Foster  |  DDN

https://www.drugdiscoverynews.com/can-precision-psychiatry-overcome-the-challenges-of-drug-development-17620 

Biomarkers could help researchers identify patients most likely to respond to psychiatric drugs, but translating early promise into clinical success remains a challenge.

Psychiatric drug development has one of the lowest success rates of any therapeutic area. One analysis found that just 7.9 percent of psychiatric drug candidates entering clinical development ultimately received regulatory approval, compared with an average of 9.6 percent across all therapeutic areas.

One challenge is that psychiatric diagnoses can encompass patients with very different underlying biology. Two people with major depressive disorder (MDD), for example, may experience similar symptoms but have different biological processes contributing to their illness and respond differently to the same treatment.

Despite this, clinical trials typically group patients by diagnosis, relying heavily on symptom scales to assess whether an experimental drug works. However, if a treatment only benefits a subset of patients, its effects may be harder to detect across the whole trial population, potentially obscuring a benefit in those most likely to respond.

There is now a growing movement to incorporate biological markers to stratify patients, monitor treatment response, and improve clinical trial design. Alto Neuroscience is among the companies pursuing this approach, combining biological and cognitive measurements with machine learning to guide psychiatric drug development.

But can this approach improve the odds of success? In 2024, Alto's investigational drug ALTO-100 failed to meet the primary endpoint in a Phase 2b trial for MDD. The result…

10/30/2026  |  Annabel Kartal Allen  |  Clinical Trials Arena

https://www.clinicaltrialsarena.com/news/geron-phase-iii-myelofibrosis-trial-termination-rare-blood-cancer/ 

Geron will now focus on Rytelo’s combinatory potential alongside SoC JAK inhibitor, Jakafi in frontline myelofibrosis.

Geron Corporation has opted to discontinue a late-stage trial evaluating its rare blood cancer drug Rytelo (imetelstat) after a forecasted efficacy miss. 

The California-based biotech hit stop on the Phase III IMpactMF trial (NCT04576156) based on a recommendation from the independent data monitoring committee, which noted that Rytelo was unlikely to meet the trial’s primary endpoint by offering significant improvements to overall survival (OS). 

Geron enrolled patients with intermediate-2 or high-risk myelofibrosis who were relapsed or refractory to a JAK inhibitor. JAK inhibitors are standard of care (SoC) in this patient population. The study had enrolled 327 patients across 144 locations, as per ClinicalTrials.gov. 

Though the data monitoring committee deemed it unlikely that Rytelo would demonstrate sufficient efficacy in myelofibrosis, researchers did find the drug to be safe for use in this patient population, as there were no new safety signals linked to the drug’s use. 

“Given the recommendation from the DMC, we believe discontinuing our Phase III IMpactMF trial at this time is the right course of action,” commented Geron’s CMO and EVP of R&D, Joseph Eid, adding that the company will now thoroughly evaluate the data and share insights to inform future myelofibrosis research. 

Myelofibrosis is a rare type of blood cancer that causes the buildup or scar tissue inside the bone marrow, thus disrupting…

10/30/2026  |  Salong Debbarma  |  Clincal Trials Arena

https://www.clinicaltrialsarena.com/news/nuvation-broaden-glioma-trial-europe/ 

The new sites build on existing trial activity in Australia, Canada, China, Japan, and the US.

Nuvation Bio is to expand its pivotal Phase III SIGMA trial into Europe to evaluate the investigational, oral, brain-penetrant, selective mutant isocitrate dehydrogenase 1 (IDH1) inhibitor safusidenib in patients with IDH1-mutant glioma.

This trial will be expanded into six study sites in France, Germany, Italy, Spain, Sweden, and the UK.

The new sites build on existing trial activity in Australia, Canada, China, Japan, and the US, where recruitment is either underway or preparing to launch.

The randomised, placebo-controlled study is evaluating safusidenib as maintenance therapy for patients with high-risk IDH1-mutant astrocytoma who have undergone standard-of-care radiotherapy or chemoradiotherapy alongside adjuvant temozolomide.

Progression-free survival, measured via blinded independent central review, serves as the primary endpoint. Around 300 participants are scheduled to take part in this main pivotal segment.

Alongside the core trial, an exploratory cohort plans to enrol nearly 40 chemotherapy- and radiotherapy-naïve participants with grade 3 IDH1-mutant oligodendroglioma to evaluate objective response rate.

Nuvation Bio founder, president and CEO David Hung said: “Our goal is to develop therapies that create a profound, positive impact on patients’ lives, and for safusidenib that means building a broad development programme that has the potential to reach more people with IDH1-mutant glioma in need of treatment options around the world.

“Expanding SIGMA to sites across six European countries is an important…

10/30/2026  |  Gina Mauro/Coral O. Omene  |  Targeted Onc.

https://www.targetedonc.com/view/why-black-women-are-underrepresented-in-breast-cancer-trials-and-what-dr-coral-omene-is-changing 

Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr Coral Omene on why.

Breast cancer does not kill equally. Across every racial and ethnic group in the United States, Black women die from breast cancer at rates up to 40% higher than their white counterparts. They are more likely to be diagnosed with triple-negative disease—the most aggressive subtype—and they are far more likely to face those odds without ever having been included in the research that produced the treatments being used to fight it.

Some FDA-approved drugs cleared trials where minority enrollment was under 2%. Others had 0 Latino patients. One had 5 Black patients total. These are not rounding errors. They are a design failure, and Coral Omene, MD, PhD, has been saying so publicly for years.

Omene is a breast medical oncologist and program director for Breast Cancer Disparities Research at Rutgers Cancer Institute in New Brunswick, New Jersey. She holds both her MD and PhD from Columbia University, runs breast cancer clinical trials as site PI for the iSPY 2 adaptive platform, and held a V Foundation grant, awarded in partnership with ESPN, specifically to increase clinical trial participation among Black women. Rutgers Cancer Institute, where she works, enrolls nearly 50% minority participants in clinical trials. She believes they may be the only institution in the country hitting that number.

On the latest episode of The Moonlight Shift, host Gina Mauro asked her what she does when a Black…

11/03/2026  |  News Medical Life Sciences

https://www.news-medical.net/news/20261103/Alliance-for-Clinical-Trials-in-Oncology-highlights-key-role-of-clinical-research-in-advancing-mens-cancer-care.aspx 

Every November, millions worldwide grow mustaches and join Movember, a global movement launched in 2003 to spark conversations about men's health, including prostate cancer, testicular cancer, and mental health. The initiative encourages men to challenge stigmas, prioritize their health, stay current with recommended screenings, and seek medical attention when symptoms arise.

Supporting Movember's mission, the Alliance for Clinical Trials in Oncology is highlighting the critical role of clinical research in advancing men's cancer care. Through greater awareness, early detection, and access to promising treatments, the Alliance aims to help improve outcomes for men with cancer and support their physical and mental well-being throughout survivorship.

With support from the National Cancer Institute, the Alliance develops and conducts clinical trials that move cancer research forward. Currently, eight ongoing studies are exploring ways to improve the detection and treatment of men's cancers, including prostate and testicular cancer, as well as enhance quality of life and support for patients and their loved ones after treatment.

Trials for people with prostate cancer
Alliance A031702: A phase II study of ipilimumab, cabozantinib, and nivolumab in rare genitourinary cancers (ICONIC)

Led by Andrea Apolo, MD, of the National Cancer Institute, this phase II trial is evaluating a combination of three anti-cancer drugs to treat rare genitourinary cancers that have spread, including primary small cell carcinoma…